Literature DB >> 15194655

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance.

G Donati1, B Stagni, F Piscaglia, N Venturoli, A M Morselli-Labate, L Rasciti, L Bolondi.   

Abstract

BACKGROUND: The conditions associated with fatty liver disease presenting with normal liver enzymes and the mechanism involved in its development remain to be fully elucidated. AIMS: The aim of the present study was to test the hypothesis that fatty liver with normal liver enzymes occurs more frequently in arterial hypertensive patients and to establish whether this condition is associated with insulin resistance. PATIENTS: A total of 55 non-obese, non-diabetic, non-heavy alcohol drinking patients with arterial hypertensive and normal liver enzymes and 55 sex and age matched healthy subjects were enrolled into the study.
METHODS: Plasma metabolic parameters, body mass index, and the presence of fatty liver were investigated. Insulin resistance was estimated from plasma insulin and glucose as the homeostasis model assessment index. Stepwise logistic regression and multivariate regression analysis were used on the combined sample to identify variables independently associated with fatty liver and insulin resistance.
RESULTS: Hypertensive patients had a significantly higher prevalence of fatty liver (30.9% v 12.7%; p<0.041), higher insulin resistance (mean 2.27 (SD 1.81) v 1.56 (0.70); p = 0.022), and slightly higher body mass index (24.9 (3.0) v 24.0 (2.2); p = 0.043) than controls. Multivariate logistic regression identified insulin resistance (odds ratio 1.66 (95% confidence interval (CI) 1.03-2.52)) and body mass index (OR 1.22 (95% CI 1.00-1.49)) as factors independently associated with fatty liver. Multivariate regression analysis showed insulin resistance to be predicted by alanine transaminase (p = 0.002), presence of arterial hypertension (p = 0.029), and body mass index (p = 0.048).
CONCLUSION: The higher prevalence of non-alcoholic fatty liver in non-obese hypertensive patients with normal liver enzymes appears to be related to increases in insulin resistance and body weight.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194655      PMCID: PMC1774102          DOI: 10.1136/gut.2003.027086

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  Ultrasound scanning in the detection of hepatic fibrosis and steatosis.

Authors:  S H Saverymuttu; A E Joseph; J D Maxwell
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

2.  Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

Authors:  T Pollare; H Lithell; C Berne
Journal:  Metabolism       Date:  1990-02       Impact factor: 8.694

3.  High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.

Authors:  Barbora Vozarova; Norbert Stefan; Robert S Lindsay; Aramesh Saremi; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

Review 4.  Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.

Authors:  B Fromenty; D Pessayre
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

5.  Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance.

Authors:  M Laakso; S V Edelman; G Brechtel; A D Baron
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.

Authors:  E E Powell; W G Cooksley; R Hanson; J Searle; J W Halliday; L W Powell
Journal:  Hepatology       Date:  1990-01       Impact factor: 17.425

8.  Insulin resistance in essential hypertension.

Authors:  E Ferrannini; G Buzzigoli; R Bonadonna; M A Giorico; M Oleggini; L Graziadei; R Pedrinelli; L Brandi; S Bevilacqua
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

9.  Liver in obesity.

Authors:  A Braillon; J P Capron; M A Hervé; C Degott; C Quenum
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

10.  Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease.

Authors:  A E Joseph; S H Saverymuttu; S al-Sam; M G Cook; J D Maxwell
Journal:  Clin Radiol       Date:  1991-01       Impact factor: 2.350

View more
  65 in total

1.  Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis.

Authors:  Yuji Shirai; Shingo Oda; Sayaka Makino; Koichi Tsuneyama; Tsuyoshi Yokoi
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

2.  Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i.

Authors:  Robert J Pattison; James Phillip Esteban; Tomoki Sempokuya; Jakrin Kewcharoen; Sumodh Kalathil; Scott K Kuwada
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

3.  Obesity-induced hepatic steatosis is mediated by endoplasmic reticulum stress in the subfornical organ of the brain.

Authors:  Julie A Horwath; Chansol Hurr; Scott D Butler; Mallikarjun Guruju; Martin D Cassell; Allyn L Mark; Robin L Davisson; Colin N Young
Journal:  JCI Insight       Date:  2017-04-20

4.  Metabolic disorders, non-alcoholic fatty liver disease and major liver resection: an underestimated perioperative risk.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Vassilis Constantinides; Claude Smadja
Journal:  J Gastrointest Surg       Date:  2012-10-09       Impact factor: 3.452

Review 5.  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.

Authors:  W Nseir; A Shalata; A Marmor; N Assy
Journal:  Dig Dis Sci       Date:  2011-06-08       Impact factor: 3.199

6.  Advances in the treatment of nonalcoholic fatty liver disease.

Authors:  Sanjeev R Mehta
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

7.  A Study of Carotid Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease.

Authors:  Sandhya Mishra; Dharamveer Yadav; Monika Gupta; Hemant Mishra; Praveen Sharma
Journal:  Indian J Clin Biochem       Date:  2012-12-29

8.  High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population.

Authors:  Tomomi Kogiso; Yuriko Moriyoshi; Satoru Shimizu; Hikaru Nagahara; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-03-07       Impact factor: 7.527

9.  Fatty liver, hypertension, and the metabolic syndrome.

Authors:  A M Diehl
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 10.  Hypertension and hepatic steatosis.

Authors:  Matthew J Brookes; Tariq H Iqbal; Brian T Cooper
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.